About 9 Meters Biopharma Inc.

9 Meters Biopharma, Inc. (Nasdaq: NMTR) is a rare, orphan and unmet needs focused GI company. The Company is advancing drug candidates for short bowel syndrome and celiac disease. 9 Meters is led by a strong management team with a history of bringing novel therapeutics to market, and the Company owns all global rights to their products, which are backed by more than 150 patents worldwide.


9 Meters is currently developing:

Long-acting GLP-1 agonist (NM-002) entering Phase 1b/2a for the treatment of short bowel syndrome in adults in mid 2020

Larazotide is currently in Phase 3 for the treatment of celiac disease in adults, with Fast Track designation from the FDA

Long-acting GLP-2 agonist (NM-003) entering Phase 1 for an undisclosed orphan indication in 2021

A dual mechanism immunomodulator (NM-004) Phase 1 ready for an undisclosed for orphan indication